Kobayashi Masayuki, Hatano Kazuo, Fukasawa Satoshi, Komaru Atsushi, Namekawa Takeshi, Imagumbai Toshiyuki, Araki Hitoshi, Hara Ryusuke, Ichikawa Tomohiko, Ueda Takeshi
Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
Int J Urol. 2015 May;22(5):477-82. doi: 10.1111/iju.12707. Epub 2015 Feb 11.
To investigate the therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate- and high-risk prostate cancer.
This was a retrospective study of 325 patients with intermediate- or high-risk prostate cancer according to the National Comprehensive Cancer Network guidelines who underwent androgen-deprivation therapy and intensity-modulated radiation therapy (76 Gy) after gold marker implantation between 2001 and 2010.
The 5-year distant metastasis-free survival rate was significantly lower for very high-risk patients than for intermediate- and high-risk patients (82.6% vs 99.4% and 96.5%, respectively; P < 0.01). The 5-year biochemical relapse-free survival rates significantly declined with increasing prostate cancer risk (P < 0.01), and were 95.9%, 87.2%, and 73.1% for the intermediate-risk, high-risk and very high-risk patients, respectively. Acute genitourinary and gastrointestinal toxicity grade ≥3 were not observed in any of the patients. Late grade 3 genitourinary toxicity occurred in 0.3% of patients.
Combination androgen-deprivation therapy and 76-Gy intensity-modulated radiation therapy with gold marker implantation offers good therapeutic outcomes with few serious complications in patients with intermediate- and high-risk prostate cancer.
探讨新辅助及同步雄激素剥夺疗法联合金标植入调强放射治疗中高危前列腺癌的疗效。
这是一项回顾性研究，根据美国国立综合癌症网络指南，对2001年至2010年间325例中高危前列腺癌患者进行研究，这些患者在植入金标后接受了雄激素剥夺疗法和调强放射治疗（76 Gy）。
极高危患者的5年无远处转移生存率显著低于中高危患者（分别为82.6%、99.4%和96.5%；P < 0.01）。5年无生化复发生存率随前列腺癌风险增加而显著下降（P < 0.01），中危、高危和极高危患者分别为95.9%、87.2%和73.1%。所有患者均未观察到急性泌尿生殖系统和胃肠道毒性≥3级。晚期3级泌尿生殖系统毒性发生率为0.3%。
雄激素剥夺疗法联合76 Gy调强放射治疗并植入金标，可为中高危前列腺癌患者带来良好的治疗效果，且严重并发症较少。
